Does a laboratory reduction establish a clinical benefit?

Does a laboratory reduction establish a clinical benefit?

No: C-POLAR has published no clinical study, and no laboratory result it publishes has been shown to produce a real-world health outcome.

The Terms of Use state: “A laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health.” The company's pathogen reports are laboratory tests of this kind; for example, Guangdong Detection Center of Microbiology, Report 2020FM20686R01E, 13 August 2020, tested a nonwoven filter medium against influenza A virus (H3N2) under ISO 18184:2014. ISO 18184 measures virus recovered from treated textile against an untreated control; it is a contact test on the medium, not an airborne or in-use result. The Viruses page shows airborne virus at 1.3 m/s airflow, NanoFlashing™ beside a control, and states: “NanoFlashing™ captures the virus, and destroys it.” The Mold page shows airborne mold spores at 1.6 m/s airflow, NanoFlashing™ beside a control, and states: “NanoFlashing™ captures the mold, and destroys it.” The Mold page also states that researchers at Massachusetts General Hospital and Harvard Medical School, in a study with funding from the U.S. National Institutes of Health, tested NanoFlashing™ with more than 100 million live, dry spores driven in by fast-moving air.

For the air filter, the label states: “It is not a medical device and is not intended to diagnose, treat, cure or prevent disease.”

Source: C-POLAR — Terms of Use, https://cpolar.tech/terms/; NanoFlashing™ Air Filter label; Guangdong Detection Center of Microbiology, Report 2020FM20686R01E, 13 August 2020; C-POLAR — Viruses, https://cpolar.tech/contaminants/viruses/; C-POLAR — Mold, https://cpolar.tech/contaminants/mold/. A copy may be made available on our review of the request.

Reviewed on 21 September 2026.